KIADIS BV and NV ORGANON enter into a discovery collaboration
Advertisement
Kiadis BV and NV Organon announced that both companies have entered into an evaluation agreement centered around the use of Kiadis' core on-line screening technology, the BioSelact(TM), for the Reproductive medicine discovery program at Organon.
Under the terms of the collaboration, Organon will supply Kiadis with a proprietary target. Financial details of the collaboration are not disclosed. Kiadis will deliver Organon with novel active compounds against the target utilizing its BioSelact(TM) technology. Organon is particularly interested in the ability of Kiadis' BioSelact(tm) technology to efficiently characterize bioactive compounds present in complex chemical mixtures.